Enzyme Replacement Therapy
Also Clin1/Clin2 ABCC6 deficiency, Clin0 calciphylaxis, RD neointimal proliferation diseases; undisclosed RD/Clin0 mineralization disorders
Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapies for patients with rare mineralization disorders. The company's unique science is based on its proprietary platform for the development of enzyme replacement therapies that use engineered enzymes to treat lysosomal storage disorders. Inozyme Pharma's lead product candidate, INZ-701, is an enzyme replacement therapy for the treatment of ENPP1 Deficiency and ABCC6 Deficiency, two rare disorders that cause abnormal mineralization of bones, teeth, and other tissues. INZ-701 is an engineered enzyme that replaces the missing or deficient ENPP1 or ABCC6 enzyme and restores normal mineralization.
Senior Director, Regulatory Strategy
Boston, US|11 days ago
Director / Senior Director, Quality and GCP Compli...
Boston, US|17 days ago